We also identify non-coding regulatory regions that associate with patient survival, including the potential clinically important 5’ UTR of CD1A, the promoter and 3’UTR of PRSS3, and the 3’UTR of SEC14L1. Finally, we identify lung cancer mutations in the splice sites of STK11 as potential driver events. This evidence concerns the gene STK11 and lung carcinoma.